Physician profile
Deepa Patel
NPI 1114453727
$8,500.13
in general payments reported to CMS, 2019-2025
25 companies · $2,126 in 2025
The $2,126 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $561 · 2023: $2,916 · 2024: $2,897 · 2025: $2,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,774 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,773.73 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $974.87 | 2022-2024 | Vtama |
| Abbvie INC. | $890.02 | 2022-2025 | |
| Janssen Biotech, INC. | $877.64 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $756.77 | 2022-2025 | |
| Incyte Corporation | $681.39 | 2022-2025 | Opzelura |
| Pfizer INC. | $575.53 | 2023-2025 | |
| Lilly USA, LLC | $541.81 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $502.41 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $446.84 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $407.96 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $386.49 | 2022-2025 | Adbry |
| Ucb, INC. | $366.93 | 2022-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.58 | 2023-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $175.19 | 2022-2025 | Siliq, Jublia, Cabtreo |
| Sun Pharmaceutical Industries INC. | $149.00 | 2023-2025 | Winlevi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $134.38 | 2024-2025 | Otezla |
| Galderma Laboratories, L.P. | $111.81 | 2024-2025 | Nemluvio, Aklief |
| Organon LLC | $74.32 | 2025 | Vtama |
| Almirall LLC | $60.26 | 2022-2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $58.71 | 2025 | Dupixent |
| Strata Skin Sciences, INC. | $39.79 | 2025 | Xtrac |
| Kerecis Limited | $34.10 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Medimetriks Pharmaceuticals, INC. | $20.34 | 2025 | |
| Mayne Pharma Commercial LLC | $19.51 | 2023 | |
| Journey Medical Corporation | $17.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.